Clinical trials: Radical Cystectomy, active
Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt
This prospective randomized controlled trial (RCT) is designed to provide high level evidence describing the non-inferiority of radical cystectomy (RC) alone versus neoadjuvant chemotherapy (NAC) plus RC on survival outcomes of…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect, Surgery
- Trial name
- NCT05776758
- Testing
- cisplatin based neoadjuvant chemotherapy, Radical cystectomy alone
- Where
- Italy
- Volunteers
- 236 people
- Sponsor
- Regina Elena Cancer Institute
Bladder Cancer
A Study of Surgical Techniques During Cystectomy
The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections after surgery.
- Trial name
- NCT06703476
- Testing
- Stent placement, Alvimopan
- Where
- 7 sites in United States
- Volunteers
- 530 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21…
- Trial name
- NCT04369560
- Testing
- Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jodi Maranchie
Urothelial Carcinoma Bladder
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries.
- Trial name
- NCT06184516
- Testing
- Reproductive organ sparing radical cystectomy, Radical cystectomy
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Florida
Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative…
- Trial name
- VOLGA (NCT04960709)
- Testing
- Durvalumab, Tremelimumab, Enfortumab Vedotin
- Where
- 196 sites in United States, Argentina and 23 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Bladder Cancer, Cystectomy
Supporting Sexual Recovery in Women With Bladder Cancer
This study looks at how bladder cancer and removing the bladder can affect women's sexual well-being. Bladder cancer can be more serious in women, and treatment like bladder removal can impact how they feel about themselves and…
- Conditions
- Bladder Cancer, Cystectomy, Female Sexual Dysfunction
- Trial name
- SPARC (NCT07091565)
- Testing
- Qualitative interview/Focus group
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- King's College London
Muscle Invasive Bladder Cancer
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with…
- Trial name
- REDEMPTED (NCT07008833)
- Testing
- Radiochemotherapy, Radical cystectomy
- Where
- Brazil
- Volunteers
- 336 people
- Sponsor
- Brazilian Clinical Research Institute
Bladder Cancer
Measuring Surgical Recovery After Radical Cystectomy
The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions.
- Trial name
- NCT03193970
- Testing
- Post-Operative Recovery Registry
- Where
- 10 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC)
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional…
- Conditions
- Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS)
- Trial name
- NCT07322263
- Testing
- Intravesical Gemcitabine and Docetaxel
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Michael A. O'Donnell
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Trial name
- SunRISe-2 (NCT04658862)
- Testing
- Cetrelimab, TAR-200, Cisplatin
- Where
- 290 sites in United States, Argentina and 23 more
- Volunteers
- 518 people
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy.
- Trial name
- NCT05792722
- Testing
- Prostate capsule-sparing radical cystectomy, Nerve sparing radical cystectomy
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Johns Hopkins University
Bladder Cancer Requiring Cystectomy, Erectile Dysfunction Following Radical Prostatectomy
Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.
This pilot study will evaluate the safety and 1-year erectile function recovery in 10 patients undergoing a novel Nerve Restoring Radical Cystectomy (NR-RC), which includes a genitofemoral nerve graft.
- Trial name
- NR-RC (NCT07140588)
- Testing
- Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.
- Volunteers
- 10 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Bladder Cancer
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
This study focuses on providing an educational program for people/participants with bladder cancer who plan to have a cystectomy (surgery) as part of their standard care.
- Trial name
- NCT06427824
- Testing
- Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery), Geriatric Service/ Discharge Planning, Questionnaires
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Bladder Cancer Requiring Cystectomy, Ileal Conduit
A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
Bladder cancer is the 4th most common cancer in men and 5th most common type of cancer in Canada. Urothelial cancer accounts for approximately 90% of malignancies.
- Conditions
- Bladder Cancer Requiring Cystectomy, Ileal Conduit, Urinary Diversion
- Trial name
- STENT-OPT (NCT06595446)
- Testing
- Early Stent removal, Late Stent removal
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
Urothelial Carcinoma Bladder
Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity
Bladder cancer (BC) is the 6th most common tumor in Europe, with over 540,000 new cases globally each year. While 75% of cases are non-muscle-invasive and treated bladder-preservingly, muscle-invasive, non-metastatic BC requires…
- Trial name
- PRACTICE (NCT06806059)
- Testing
- Physical Activity
- Where
- Germany
- Volunteers
- 146 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current…
- Trial name
- KEYNOTE-B15 (NCT04700124)
- Testing
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND
- Where
- 188 sites in United States, Argentina and 27 more
- Volunteers
- 808 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer, Cancer of the Bladder, Recurrent
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers.
- Conditions
- Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
- Trial name
- CISTO (NCT03933826)
- Where
- 36 sites in United States
- Volunteers
- 570 people
- Sponsor
- University of Washington
Non-metastatic Bladder Cancer
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
This will be an open-label, single group supportive care pilot study in which patients are given cannabinoid gummies in the perioperative setting to alleviate RC/UD symptoms and improve quality of life.
- Trial name
- NCT07577999
- Testing
- Cannabigerol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Bladder Cancer, Bladder Cancer, Metastatic
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer.
- Trial name
- TOMBOLA (NCT04138628)
- Testing
- Atezolizumab
- Where
- 5 sites in Denmark
- Volunteers
- 154 people
- Sponsor
- Jørgen Bjerggaard Jensen
Bladder Cancer, Bladder
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630
he primary objective is to characterize the safety profile of UGN-201 in patients with urothelial carcinoma undergoing radical cystectomy.
- Trial name
- NCT05055050
- Testing
- UGN-201
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center